How have AZNCF shares performed in 2024?

AstraZeneca's stock was trading at $134.45 at the start of the year. Since then, AZNCF stock has increased by 4.2% and is now trading at $140.15. View the best growth stocks for 2024 here .

Are investors shorting AstraZeneca?

AstraZeneca saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 67,800 shares, an increase of 15.9% from the March 15th total of 58,500 shares. Based on an average trading volume of 3,300 shares, the days-to-cover ratio is presently 20.5 days. View AstraZeneca's Short Interest .

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Friday, February 9th. Stockholders of record on Friday, February 23rd will be paid a dividend of $1.97 per share on Monday, March 25th. The ex-dividend date of this dividend is Wednesday, February 21st. This is a boost from the stock's previous dividend of $0.93. Read our dividend analysis for AZNCF .

Is AstraZeneca a good dividend stock?

AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for AZNCF .

How do I buy shares of AstraZeneca?

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Price, News & Analysis

→ Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad)

Free AZNCF Stock Alerts

$140.15

+4.84 (+3.58%)

(As of 04/17/2024 ET)

Compare

Today's Range: $140.15
▼
$140.15
50-Day Range: $120.66
▼
$140.15
52-Week Range: $118.16
▼
$153.10

Volume: 559 shs
Average Volume: 2,953 shs
Market Capitalization: N/A

P/E Ratio: 171.75
Dividend Yield: 2.00%
Price Target: N/A

Stock Analysis Chart Dividend Financials Headlines Ownership SEC Filings Short Interest

Get AstraZeneca alerts:

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.03
Based on 20 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.11 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for AstraZeneca.

0.0

Short Interest

Percentage of Shares Shorted
Short Interest Ratio / Days to Cover
AstraZeneca has a short interest ratio ("days to cover") of 20.5, which indicates bearish sentiment.
Change versus previous month
Short interest in AstraZeneca has recently increased by 15.90%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Leadership
AstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AZNCF.

2.2

News and Social Media Coverage

News Sentiment
AstraZeneca has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 20 news articles for AstraZeneca this week, compared to 8 articles on an average week.
MarketBeat Follows
1 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.
Percentage Held by Institutions
40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 171.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 139.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 171.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 250.16.

See Top Rated MarketRank™ Stocks Here

Ad Daily Market Alerts

Top 5 Tech Stocks to Buy for 2024

Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.

Click here to sign up for our free report & newsletter

About AstraZeneca Stock (OTCMKTS:AZNCF)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZNCF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AZNCF Stock News Headlines

April 17, 2024 | msn.com

AstraZeneca’s Imfinzi shows overall survival benefit in Phase III BTC trial

April 16, 2024 | lse.co.uk

AstraZeneca's hails Imfinzi survival data on cancer form

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 15, 2024 | msn.com

Adherium’s Smartinhaler gains clearance for use with AstraZeneca devices

April 14, 2024 | thetimes.co.uk

Proxy advisory groups under fire after AstraZeneca pay row

April 14, 2024 | ft.com

Proxy advisers inflict ‘serious harm’ to UK, says AstraZeneca chair

April 14, 2024 | ft.com

AstraZeneca chair: UK business needs a level playing field to compete

April 14, 2024 | americanbankingnews.com

AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 15.9% in March

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 12, 2024 | thetimes.co.uk

The Times view on AstraZeneca CEO: Worth Every Penny

April 12, 2024 | msn.com

AstraZeneca CEO set to earn £18.7 million after shareholder backing

April 11, 2024 | msn.com

AstraZeneca announces dividend hike ahead of CEO pay vote

April 11, 2024 | marketwatch.com

AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval

April 11, 2024 | msn.com

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

April 11, 2024 | finance.yahoo.com

FTSE 100 Live: Focus turns to GDP after shares close lower following ECB rates hold, AstraZeneca pay revolt

April 11, 2024 | msn.com

The boss of AstraZeneca could earn £18.5m this year - but he may be underpaid

April 11, 2024 | money.usnews.com

AstraZeneca Shareholders Approve 2024 Pay Policy in Boost to CEO Soriot

April 11, 2024 | bloomberg.com

AstraZeneca Shareholders Vote in Favor of £19 Million CEO Pay

April 11, 2024 | msn.com

AstraZeneca hikes dividend as investors vote on chief executive's pay

April 11, 2024 | theguardian.com

AstraZeneca promises dividend rise hours before vote on boss’s £19m pay deal

April 11, 2024 | ft.com

AstraZeneca promises dividend increase ahead of key vote on chief’s pay

April 11, 2024 | mirror.co.uk

AstraZeneca's dividend increase pledge ahead of vote on chief's £18.7m pay deal

April 10, 2024 | ft.com

AstraZeneca’s Pascal Soriot ‘massively underpaid’ at £16.9mn, says top shareholder

April 10, 2024 | msn.com

Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO

April 10, 2024 | thetimes.co.uk

AstraZeneca boss is ‘massively underpaid’ on £17m

April 8, 2024 | lse.co.uk

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

April 8, 2024 | msn.com

AstraZeneca and Daiichi Sankyo’s drug gets USFDA nod for people with HER2-positive solid tumours

See More Headlines

Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/25 Dividend: 2/21/2024
Dividend Payable: 3/25/2024
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Current Symbol: OTCMKTS:AZNCF
CUSIP: N/A
CIK: 901832
Web: www.astrazeneca.com
Phone: 442037495000
Fax: N/A
Employees: 89,900
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 171.75
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Pascal Soriot D.V.M. (Age 65)
M.B.A., CEO & Executive Director
Comp: $5.76M
Dr. Aradhana Sarin M.D. (Age 50)
CFO & Executive Director
Comp: $3.18M
Ms. Pam P. Cheng (Age 54)
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Mr. Andrew P. Barnett
Head of Investor Relations
Mr. Jeffrey Pott
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Gonzalo Vina
Head of Global Media Relations
Dr. Menelas Nicolas Pangalos Ph.D. (Age 57)
Executive Vice-President
Dr. Ruud Dobber Ph.D.
Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D. (Age 58)
Ph.D., Executive Vice President of Oncology Research & Development
Mr. Leon Wang
Executive VP of International & China President

Key Competitors

View All Competitors

AZNCF Stock Analysis - Frequently Asked Questions

How have AZNCF shares performed in 2024?: AstraZeneca's stock was trading at $134.45 at the start of the year. Since then, AZNCF stock has increased by 4.2% and is now trading at $140.15.
View the best growth stocks for 2024 here.
Are investors shorting AstraZeneca?: AstraZeneca saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 67,800 shares, an increase of 15.9% from the March 15th total of 58,500 shares. Based on an average trading volume of 3,300 shares, the days-to-cover ratio is presently 20.5 days.
View AstraZeneca's Short Interest.
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?: AstraZeneca announced a dividend on Friday, February 9th. Stockholders of record on Friday, February 23rd will be paid a dividend of $1.97 per share on Monday, March 25th. The ex-dividend date of this dividend is Wednesday, February 21st. This is a boost from the stock's previous dividend of $0.93.
Read our dividend analysis for AZNCF.

Is AstraZeneca a good dividend stock?: AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZNCF.
How do I buy shares of AstraZeneca?: Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:AZNCF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AstraZeneca (AZNCF) Stock Price, News & Analysis

AstraZeneca MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AstraZeneca Stock (OTCMKTS:AZNCF)

AZNCF Stock Price History

AZNCF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AZNCF Stock Analysis - Frequently Asked Questions

Overall MarketRank^™